⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 29, 2022The Journal of Infectious DiseasesOpen Access

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct03814590.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leroux‐Roels et al. (2022) studied this question.

synapsesocial.com/papers/69d89b7d8cb8f39931ae35e3 https://doi.org/10.1093/infdis/jiac327

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trialRCT · 2016 · 113 citations
2Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in AdultsOriginal Research · 2004 · 183 citations
3A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum AdjuvantEarly-Phase Clinical Trial · 2016 · 67 citations
4Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primatesOriginal Research · 2021 · 80 citations
5Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 TrialsEarly-Phase Clinical Trial · 2018 · 47 citations